Blog

2 Nasdaq-100 Stocks That Are No-Brainer Buys in November, and 1 to Avoid Like the Plague

Wall Street has been nothing short of a roller-coaster ride since this decade began. Over nearly four years, the major stock indexes have vacillated between bull and bear markets, with the pendulum

TheMotleyFool

0

2 Stocks That Are Running Circles Around Nike

For its long-term buy-and-hold shareholders, Nike (NYSE: NKE) stock has been a true wealth builder. A small $1,000 investment into the sportswear and sneaker company 40 years ago would have been

TheMotleyFool

0

The S&P 500 Just Had Its Best Week of 2023. 2 Artificial Intelligence (AI) Stocks to Buy Before the Stock Market Rallies Further.

The S&P 500 has been in rally mode this year, and after a brief stumble, the upward trend has resumed. In the week ended Nov. 3, the widely followed index jumped nearly 6%, marking its best

TheMotleyFool

0

Got $1,000? These 2 Artificial Intelligence (AI) Stocks Are Screaming Buys Right Now

Artificial intelligence (AI) is one of the hottest stock market themes of 2023, as the growing prominence of this technology is driving tangible gains for many companies.

Nvidia (NASDAQ: NVDA)

TheMotleyFool

0

This Magnificent High-Yield Dividend Stock Thinks Its Shares Are a Buy (and It's Putting Money Behind That View)

This year has been the best of times and the worst of times for Brookfield Renewable (NYSE: BEP)(NYSE: BEPC). On the one hand, the company is having a stellar year. It has secured several

TheMotleyFool

0

Is Digital Realty Stock a Buy?

Investors had a muted reaction to the third-quarter earnings report for Digital Realty Trust (NYSE: DLR). The data center company has struggled amid a sluggish economy and a slowdown in the increase

TheMotleyFool

0

Down 34% to 57%, These Dividend Stocks Are Screaming Buys

Looking beyond the biggest of the mega-cap tech stocks, 2023 probably hasn't been a very good year for your portfolio. That's not great for our current holdings, but if you have more money to

TheMotleyFool

0

Nearly Half of Warren Buffett's More Than $6 Billion in Annual Dividend Income Comes From Just 3 Stocks

For nearly six decades, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett has been dazzling Wall Street and everyday investors with his investing prowess. Even with an occasional bad

TheMotleyFool

0

Shopify Stock Is Soaring Again: Should You Buy Shares?

The bull market is back, and so is pandemic favorite Shopify (NYSE: SHOP). After posting robust growth and showing strong operating leverage in the third quarter, the e-commerce platform gained more

TheMotleyFool

0

Gamification Is Bad News for Stock Investors, Particularly if the Trading Is Free

It should be obvious, but brokers are in business to make money. So when they offer you something for free, you need to ask why and how. When it comes to free stock trades, the answers are

TheMotleyFool

0

Are Tax Hikes the Only Solution to Social Security's Impending Financial Shortfall?

Social Security is on the verge of a major financial crunch. In the coming years, the program expects to owe more in scheduled benefits than it collects in payroll tax revenue (its primary source of

TheMotleyFool

0

Enphase Stock Is Crashing: Is This 1 Thing a Huge Warning for Investors?

Enphase Energy (NASDAQ: ENPH) stock has fallen sharply in 2023, despite still being a huge long-term winner. Investors are beginning to wonder if the one thing Motley Fool contributors Jason Hall

TheMotleyFool

0

Disney Stock May Get Another Boost From First Dividend Payment in Almost 4 Years: Should You Buy the Rebound?

It's been a tough few years for Walt Disney (NYSE: DIS) investors. Since the stock hit an all-time high of $201.91 on March 8, 2021, it has been ravaged, losing more than half its value and falling

TheMotleyFool

0

AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock?

For the past couple of years, investors looked ahead to one particular thing with dread: AbbVie's (NYSE: ABBV) blockbuster immunology drug facing competition. After all, at its peak, Humira brought

TheMotleyFool

0